10-Q: Tempus AI Reports Strong Revenue Growth, Strategic Acquisitions

Tempus AI, Inc. announced significant revenue increases and strategic acquisitions in its latest 10-Q filing, alongside new debt financing and ongoing legal challenges.

Summary

• Total net revenue for the three months ended September 30, 2025, increased by 85% to $334.2 million, up from $180.9 million in the prior year period.
• Genomics revenue surged by 117% to $252.9 million, primarily driven by the acquisition of Ambry Genetics Corporation and increased oncology testing volume and reimbursement rates.
• Data and services revenue grew by 26% to $81.3 million, fueled by demand for Insights products and the Pathos Foundation Model agreement.
• Net loss for the three months ended September 30, 2025, was $(79.98) million, a slight increase from $(75.84) million in the same period last year.
• Adjusted EBITDA improved significantly, turning positive to $1.5 million for the three months ended September 30, 2025, compared to $(21.8) million in the prior year.
• The company completed three key acquisitions: Paige.AI, Inc. for digital pathology, Ambry Genetics Corporation for hereditary cancer screening, and Deep 6 AI, Inc. for AI-powered clinical trial matching.
• Tempus AI raised $725.7 million net proceeds from a private offering of 0.75% Convertible Senior Notes due 2030 and $195.5 million net from an At-the-Market (ATM) offering of Class A common stock.
• The company reincorporated from a Delaware corporation to a Nevada corporation effective August 7, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth and significant improvement in Adjusted EBITDA, indicating positive operational momentum. Strategic acquisitions and substantial capital raises position it for future expansion. While net losses persist and legal challenges exist, the overall trajectory and financial strengthening are positive.

Positives

• Total net revenue increased by 85% to $334.2 million for the three months ended September 30, 2025, demonstrating strong top-line growth.
• Genomics revenue more than doubled, growing 117% to $252.9 million, largely due to the successful integration of Ambry Genetics and higher test volumes.
• Adjusted EBITDA turned positive to $1.5 million for the three months ended September 30, 2025, indicating improved operational efficiency.
• Strategic acquisitions of Paige.AI, Ambry Genetics, and Deep 6 AI expand the company's dataset, technology portfolio, and market reach into digital pathology, hereditary cancer screening, and clinical trial matching.
• Successful capital raises through $750.0 million Convertible Senior Notes and $195.5 million from an At-the-Market offering significantly bolstered liquidity.
• Reduced net loss for the nine months ended September 30, 2025, to $(190.9) million from $(692.8) million in the prior year, indicating progress towards profitability.
• Increased average revenue per Oncology test from approximately $1,530 to $1,600, driven by improved Medicare reimbursement rates.

Negatives

• Net loss for the three months ended September 30, 2025, slightly increased to $(79.98) million from $(75.84) million in the prior year period.
• Operating loss increased to $(60.99) million for the three months ended September 30, 2025, from $(53.61) million in the prior year.
• Incurred a $12.0 million loss on debt extinguishment due to the repayment of the Term Loan Facility.
• Net cash used in operating activities increased to $(181.3) million for the nine months ended September 30, 2025, from $(149.8) million in the prior year, indicating higher cash burn.
• Net cash used in investing activities significantly increased to $(387.6) million for the nine months ended September 30, 2025, primarily due to acquisitions.
• Interest expense increased by 12% to $(15.4) million for the three months ended September 30, 2025, due to new debt facilities.

Risks

• Servicing debt obligations, including the $750.0 million Convertible Senior Notes, requires a certain level of cash flow or financing, and the ability to make scheduled payments depends on future performance.
• The conditional conversion feature of the Notes, if triggered, could require the company to reclassify a portion of the outstanding principal as a current liability, materially reducing net working capital.
• Conversion of Notes into Class A common stock could result in dilution to stockholders and downward pressure on the stock price.
• The Capped Call transactions, intended to reduce dilution, are subject to counterparty risk, and a default by an option counterparty could lead to more dilution.
• Ongoing legal proceedings, including patent infringement lawsuits from Guardant Health Inc. and a federal securities class-action lawsuit, could result in significant costs, diversion of management resources, and adverse impacts on the business.
• Government investigations from the Ohio Attorney General and the U.S. Attorneys Office regarding billing practices and compliance with the False Claims Act and Anti-Kickback statute pose regulatory and financial risks.
• The company expects to become a large accelerated filer and no longer qualify as an emerging growth company as of December 31, 2025, which will increase compliance costs and reporting requirements.
• Future capital requirements will depend on spending on research and development and growth-related expenditures, and additional capital may not be available on reasonable terms or at all.

Future Outlook

The company expects to maintain high levels of investment in product innovation, including new laboratory assays, algorithm development, and expansion into new disease areas. Significant investments in the technology platform are planned to improve user experience and data processing efficiency. The company anticipates continued growth in customer acquisition and expansion of partnerships with existing customers across its Genomics, Data, and AI Applications product lines. It also expects to become a large accelerated filer by December 31, 2025, which will increase operating costs. The company believes its current liquidity will be sufficient for more than twelve months, but may seek additional capital for business expansion or strategic investments.

Management Comments

• "We believe Intelligent Diagnostics represent the future of precision medicine, informing more personalized and data-driven therapy selection and development."
• "We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare."
• "Our financial performance relies heavily on our ability to secure reimbursement from payers and government health benefits programs."
• "We will continue to invest significantly in various efforts aimed at improving our average reimbursement, including performing clinical studies to generate evidence of clinical utility, seeking regulatory approval for our tests, and opening additional lab locations."
• "We expect that our selling, general and administrative expenses will continue to increase in absolute dollars after our IPO, primarily due to increased headcount and costs associated with operating as a public company."

Industry Context

Tempus AI operates at the intersection of healthcare and technology, leveraging AI and machine learning to enhance diagnostics and personalize medicine. The company's strategy of combining deep healthcare expertise with leading technology capabilities positions it uniquely against traditional diagnostic labs and pure-play technology companies. Its expansion into digital pathology (Paige.AI), hereditary cancer screening (Ambry Genetics), and AI-powered clinical trial matching (Deep 6 AI) reflects a broader industry trend towards integrated, data-driven healthcare solutions. Collaborations with pharmaceutical giants like AstraZeneca and GlaxoSmithKline, and a partnership with Recursion Pharmaceuticals, highlight the growing demand for de-identified patient data and AI applications in drug discovery and development. The focus on Intelligent Diagnostics aligns with the industry's shift towards precision medicine, aiming to improve patient outcomes and accelerate therapeutic development.

Comparison to Industry Standards

• The company's rapid revenue growth (85% in Q3 2025) significantly outpaces many established diagnostic and healthcare technology companies, indicating strong market penetration and successful integration of acquisitions.
• The positive Adjusted EBITDA for Q3 2025 ($1.5 million) is a notable improvement, suggesting a move towards profitability, which is a key benchmark for growth-stage companies in the biotech and AI sectors, often characterized by initial heavy losses.
• The acquisition of Ambry Genetics, a leader in hereditary cancer screening, positions Tempus AI to compete more directly with established genetic testing providers like Invitae (though Invitae has faced financial challenges) and Color Genomics, expanding its offerings beyond oncology.
• The acquisition of Paige.AI establishes a footprint in digital pathology, a rapidly evolving field with players like PathAI and Paige's previous competitors, indicating Tempus AI's intent to be a comprehensive AI diagnostics leader.
• The $750 million Convertible Senior Notes offering and $500 million ATM offering demonstrate strong capital market access, comparable to well-capitalized biotech firms, enabling continued investment in R&D and strategic growth, unlike smaller, cash-strapped startups.
• The company's average reimbursement for NGS tests in oncology ($1,600 in Q3 2025) is a critical metric for diagnostic companies, and its efforts to improve this rate are standard practice in the highly regulated and payer-dependent diagnostics market.

Corporate Governance

Legal Proceedings

• Guardant Health Inc. filed multiple patent infringement complaints against Tempus AI's liquid biopsy products (Tempus xF, xF+, xM Monitor, xM MRD) in the U.S. District Court for the District of Delaware, seeking injunctive relief, monetary damages, and future royalties.
• Tempus AI filed counterclaims against Guardant Health Inc. under the Lanham Act for false and misleading advertisements and a separate patent infringement complaint against Guardant's products in the U.S. District Court for the Southern District of California.
• A federal securities class-action lawsuit, Shouse v. Tempus AI, Inc. et al, was filed on June 12, 2025, alleging false or misleading statements by the company and its executives between August 6, 2024, and May 27, 2025.
• Received a subpoena from the Office of the Ohio Attorney General on May 19, 2022, requesting billing and patient records for Ohio Medicaid patients, to which the company responded.
• Received a Civil Investigative Demand (CID) from the U.S. Attorneys Office for the Eastern District of New York on March 4, 2024, requesting documents related to compliance with the False Claims Act, Anti-Kickback statute, and Medicare 14-Day rule.

Related Party Transactions

• The company has a remaining related party liability of $0.5 million as of September 30, 2025, from assuming an office lease in 2018.
• Subleases a portion of office space to this related party, with insignificant sublease income.
• Entered into the Pathos Master Agreement with Pathos AI, Inc. (co-founded by Tempus AI's CEO), for Foundation Model development and data licensing.
• Pathos will pay Tempus AI data license fees of $200 million over a three-year period, including an upfront payment of $50 million received as of April 2025.
• Tempus AI will pay Pathos $35 million in consideration of Pathos' commitments under the Pathos Master Agreement.
• Recognized $25.2 million of revenue from Pathos for the three months ended September 30, 2025, and $41.7 million for the nine months ended September 30, 2025.
• As of September 30, 2025, related party assets were $5.7 million (current) and $19.3 million (long-term), representing future services to be provided by Pathos.
• Related party deferred revenue of $19.9 million is included in current deferred revenue as of September 30, 2025.

Stakeholder Impact

• Shareholders: Potential dilution from convertible notes and ATM offering, but also benefit from increased liquidity and strategic growth. Class B shareholders retain significant voting control.
• Employees: Acquisitions (Paige, Ambry, Deep 6) expand the workforce and create new opportunities, but also integration challenges. Stock-based compensation remains a significant component of employee incentives.
• Customers (Physicians, Research Institutions, Pharma/Biotech): Benefit from expanded product offerings (Genomics, Data, AI Applications), including hereditary testing and digital pathology, and enhanced clinical trial matching services.
• Creditors: New debt facilities (Convertible Senior Notes, Credit Facilities) increase leverage but are intended to fund strategic growth. Compliance with debt covenants is crucial.
• Regulatory Bodies: Subject to ongoing government investigations and increased scrutiny as the company approaches large accelerated filer status, requiring robust compliance efforts.

Next Steps

• Continue to invest in product innovation, including new laboratory assays, algorithm development, and expansion into new disease areas.
• Maintain high levels of investment in the technology platform to improve user experience and data processing efficiency.
• Focus on customer acquisition and expansion of partnerships with existing customers across Genomics, Data, and AI Applications product lines.
• Work to improve average reimbursement rates through clinical studies, regulatory approvals, and additional lab locations.
• Prepare for increased compliance costs and reporting requirements as the company expects to become a large accelerated filer by December 31, 2025.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-06, ASU 2025-07) on future disclosures and financial statements.

Key Dates

Recommendation

Tempus AI demonstrates strong revenue growth, particularly in its Genomics segment, driven by strategic acquisitions and increased test volumes. The significant improvement in Adjusted EBITDA indicates a positive operational trajectory. However, the company continues to incur net losses and has increased its debt load through convertible notes and credit facilities, introducing new financial risks. Ongoing legal proceedings and government investigations also present uncertainties. While the long-term potential in AI-driven healthcare is substantial, the current financial position, coupled with the inherent risks of a rapidly evolving and competitive market, suggests a 'hold' recommendation. Investors should monitor the company's path to profitability, successful integration of acquisitions, and outcomes of legal and regulatory matters before considering further investment.

Keywords

Genomics, AI, Healthcare Technology, Digital Pathology, Clinical Trials, Cancer Screening, Biotechnology, Pharmaceutical, SEC Filing, 10-Q, Convertible Notes, Acquisitions